Aplagon secures funding to support Phase IIa trial of APAC therapeutic

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic, APAC, to primarily support the initiation of a Phase IIa trial for peripheral arterial occlusive disease/chronic limb-threatening ischaemia (PAOD/CLTI) in Finland.